Journal
Henry Meds vs bmiMD: The Flat-Rate Flagship Against the Ladder Champion
Released: Last reviewed:
The short answer
Molecule by molecule, the arithmetic splits cleanly. Semaglutide: bmiMD wins outright — $129 month-to-month against Henry's $179, falling to $99 on the twelve-month tier, a $50–$80 monthly gap with no structural offset. Tirzepatide: closer, and shape-dependent — the monthly rates tie at $179, bmiMD's $139 twelve-month tier (billed monthly) beats anything Henry offers, and Henry's counters are qualitative: the published 41-state footprint with stated exclusions, the one-price-every-molecule simplicity, and an oral option bmiMD lacks. Both carry "reported" status from independent 2026 captures; neither publicly names its pharmacy (bmiMD advertises a named-503A claim to cash at intake), and both clear the ad-matches-checkout bar. The routing: price-first buyers of either molecule → bmiMD; simplicity-and-footprint buyers at tirzepatide's monthly tier → the coin stays in the air until the intake answers land.
The tie-breakers, since the prices nearly tie
On tirzepatide month-to-month — the one genuinely contested lane — five questions settle it. Commitment appetite: any willingness to commit twelve months hands bmiMD the $40/month win; pure flexibility keeps the tie. Pharmacy answers: bmiMD's advertised named-503A claim, cashed into an actual name and verified, beats Henry's silence — unless Henry's intake produces a name first; either way the fifteen minutes decides more than the ten dollars ever could. State certainty: Henry publishes its map (including the nine exclusions); bmiMD confirms at intake — a wash for most, decisive at the margins. Dose economics: both are dose-flat, neutralizing the market's favorite trap identically. Exit terms: both month-to-month tiers should confirm cancellation mechanics in writing; bmiMD's committed tiers add the early-exit question its review scripts. The meta-answer this comparison keeps teaching: when two well-behaved programs converge on price, verification quality becomes the product — and the one that answers faster, in writing, deserves the charge.
Questions people ask
Is Henry Meds or bmiMD cheaper?
Semaglutide: bmiMD, decisively — $129 vs $179 monthly, $99 on its twelve-month tier. Tirzepatide: tied at $179 month-to-month; bmiMD's $139 twelve-month plan (billed monthly) wins for anyone willing to commit. Henry's edge is structural: published 41-state map, one flat price, an oral option.
Which is more trustworthy, Henry or bmiMD?
Both carry 'reported' status from independent 2026 captures and clean ad-matches-checkout behavior; neither publicly names its pharmacy (bmiMD advertises a named-503A claim — cash it at intake). The practical test: whichever produces its pharmacy name and written terms faster earns the verification win.
Should I just pick NexLife instead of either?
It is our editor's pick (#1 overall, methodology v4.1). As of November 6, 2026, NexLife lists compounded tirzepatide at $129 a month on its monthly plan and $115 on 12 months, and semaglutide at $109 and $95, the same price at every dose with no membership; its plan pages name three state-licensed 503A pharmacies. That is below Henry's $179 starting price on tirzepatide. On semaglutide, bmiMD's last-captured $129 monthly was lower. NexLife is not the lowest price we track: Eden lists the same $129 for tirzepatide and $99 for semaglutide (October 15, 2026).
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.